Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

Clinical trial NCT06418477 · RECRUITING

Trial details

NCT number: NCT06418477
Sponsor: Peking University People's Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Monoclonal Gammopathy of Renal Significance

Start date: 2024-06-15
Primary completion: 2025-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.